TNF superfamily receptors

Search documents
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Globenewswire· 2025-10-02 11:51
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be ...
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Globenewswire· 2025-08-21 14:17
Core Insights - Shattuck Labs, Inc. is developing SL-325, a potentially first-in-class DR3 antagonist antibody aimed at treating Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases [1][5] - The company plans to dose the first participant in its Phase 1 clinical trial in healthy volunteers in Q3 2025, with enrollment expected to be completed by Q2 2026 [2][4] - Current cash and cash equivalents, along with anticipated proceeds of up to $103 million from a recent private placement, are expected to fund operations into 2029 [1] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for autoimmune and inflammatory diseases, focusing on novel therapeutics targeting TNF superfamily receptors [5] - The company has offices in Austin, Texas, and Durham, North Carolina [5] Clinical Development - SL-325 is designed to achieve a complete and durable blockade of the DR3/TL1A pathway, with preclinical studies showing high-affinity binding and superior activity compared to TL1A antibodies [4] - The Phase 1 clinical trial will evaluate safety, tolerability, and pharmacokinetics through a randomized, double-blind, placebo-controlled design [2]
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire· 2025-08-14 10:30
Core Insights - Shattuck Labs, Inc. has submitted an Investigational New Drug (IND) application for SL-325, with clearance expected in Q3 2025, and plans to begin dosing the first participant in a Phase 1 clinical trial in the same quarter [1][6][10] - The company reported a cash balance of approximately $50.5 million at the end of Q2 2025, with additional funding from a recent oversubscribed private placement expected to support operations into 2029 [1][9] - SL-325 is a first-in-class DR3 blocking antibody aimed at treating inflammatory bowel disease (IBD) and other immune-mediated diseases, with multiple preclinical bispecific antibodies also in development [6][10][11] Recent Developments - The second quarter of 2025 was marked by the successful submission of the IND application to the FDA, with expectations to start enrollment in the Phase 1 trial later this quarter and complete it by Q2 2026 [2][6] - The Phase 1 trial will assess safety, tolerability, immunogenicity, and pharmacokinetics in healthy volunteers, with the first participant expected to be dosed in Q3 2025 [6][10] - Shattuck is also developing multiple preclinical DR3-based bispecific antibodies targeting IBD and plans to nominate a lead candidate from this pipeline in 2025 [6][10] Financial Performance - As of June 30, 2025, cash and cash equivalents were approximately $50.5 million, down from $105.3 million a year earlier [13] - Research and Development (R&D) expenses for Q2 2025 were $8.7 million, a decrease from $19.2 million in Q2 2024 [13] - The net loss for Q2 2025 was $12.5 million, or $0.24 per share, compared to a net loss of $21.6 million, or $0.42 per share, in the same quarter of the previous year [13][19]
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
Globenewswire· 2025-05-01 20:20
Core Insights - Shattuck Labs, Inc. is advancing its SL-325 program with an IND filing expected in the third quarter of 2025, targeting inflammatory bowel disease (IBD) and other immune-mediated diseases [1][5][9] - The company reported a cash balance of approximately $60.9 million as of March 31, 2025, which is expected to fund operations into 2027 [1][8] Company Developments - SL-325 is a potentially first-in-class DR3 antagonist antibody designed to block the DR3/TL1A pathway, with the Phase 1 clinical trial set to evaluate safety, tolerability, and pharmacokinetics [5][9] - The first patient for the SAD portion of the Phase 1 trial is expected to be enrolled in the third quarter of 2025, with completion of enrollment anticipated by the second quarter of 2026 [5][9] - The company has completed wind-down activities related to discontinued oncology programs and is well-positioned to fund operations beyond the Phase 1 trial results [2][5] Financial Performance - For the first quarter of 2025, Shattuck Labs reported R&D expenses of $9.9 million, down from $16.3 million in the same quarter of 2024, and G&A expenses of $4.5 million, slightly down from $4.9 million [12][19] - The net loss for the quarter was $13.7 million, or $0.27 per share, compared to a net loss of $18.5 million, or $0.37 per share, in the first quarter of 2024 [12][19] - Cash and cash equivalents decreased from $114.6 million as of March 31, 2024, to $60.9 million as of March 31, 2025 [12][19] Upcoming Events - Shattuck Labs participated in the 24th Annual Needham Virtual Healthcare Conference and presented at the ECCO in February 2025 [5][12] - The company is scheduled to present at the PEGS Boston Summit on May 12, 2025, and will participate in the Leerink Partners Therapeutics Forum on July 8-9, 2025 [12]